NCT05896371View on ClinicalTrials.gov

A Phase 1/2 Study of Personalized PSMA Radiopharmaceutical Therapy

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

500

Participants

Timeline

Start Date

March 31, 2028

Primary Completion Date

March 31, 2033

Study Completion Date

March 31, 2034

Conditions
CancerProstate CancerMetastatic CancerMetastatic Prostate Cancer
Interventions
DRUG

177Lu-PSMA-I&T - escalating renal absorbed dose

Personalized 177Lu-PSMA-I\&T injected activity

DRUG

177Lu-PSMA-I&T - recommended phase 2 regime

Personalized 177Lu-PSMA-I\&T injected activity

All Listed Sponsors
collaborator

Canadian Institutes of Health Research (CIHR)

OTHER_GOV

lead

CHU de Quebec-Universite Laval

OTHER